

Appendix 3. Results

Contents

3a Proportion of patients responding to each survey	2
3b Vaccine related beliefs- Oxford Complacency and Confidence Scale- Adults	3
3c Vaccine related beliefs- Oxford Complacency and Confidence Scale- Children	4
3d Grade and attribution of investigator-reported Serious Adverse Events	5
3e Investigator-determined attribution of Serious Adverse Events.....	6
3f Category of Participant reported adverse events	7
3g Specific Participant reported adverse events	8
3h Association of worst patient reported adverse event with receipt of 3 rd vaccine dose... 12	
3i Investigator- reported adverse events by vaccine type (this is way too long and explanations are better below table- already there).....	13
3j Serious Adverse Events by vaccine type	15
3k Participant-reported adverse effects by vaccine type	17
3l Impact of sequential vaccine doses on health-related quality of life in adults	20
3m Impact of sequential doses on health-related quality of life in children.....	22
3n Baseline health-related quality of life and vaccine related beliefs.....	25

3a Proportion of patients responding to each survey

Surveys were issued as per schedule in Figure 1.

Activity completed	Adults N=392	Children (5-19yrs)* N=107
Dose 1		
Received dose	392	107
Pre-dose QLQ-C30	379	4
Pre-dose PedsQL	N/A	45
Pre-dose PedsQL proxy	N/A	54
Vaccine beliefs	387	56
Parent vaccine beliefs	N/A	58
Post-dose QLQ-C30	368	4
Post-dose PedsQL	N/A	39
Post-dose PedsQL proxy	N/A	55
Patient-reported AEs	371	54
Dose 2		
Received dose	383	104
Pre-dose QLQ-C30	369	5
Pre-dose PedsQL	N/A	45
Pre-dose PedsQL proxy	N/A	50
Post-dose QLQ-C30	362	4
Post-dose PedsQL	N/A	32
Post-dose PedsQL proxy	N/A	46
Patient-reported AEs	367	28
Dose 3		
Received dose	320	79
Vaccine beliefs	318	3
Parent vaccine beliefs	N/A	0
Post-dose QLQ-C30	281	4
Post-dose PedsQL	N/A	19
Post-dose PedsQL proxy	N/A	29
Patient-reported AEs	288	27
Follow-up		
Follow-up QLQ-C30	312	3
Follow-up PedsQL	N/A	38
Follow-up PedsQL proxy	N/A	0
Medical record review	388	104

N = number; N/A = not applicable

* 18 and 19 year-olds received either QLQ-C30 or PedsQL questionnaires depending if enrolled at an adult or children's cancer centre.

3b Vaccine related beliefs- Oxford Complacency and Confidence Scale- Adults

	Dose 1 (N = 387)	Dose 3 (N = 318)
Importance		
N	357	269
Mean (SD)	17.0 (10.6)	18.4 (12.6)
Median (IQR)	15.0 (10.0 - 25.0)	18.8 (10.0 - 25.0)
Unknown (%)	30 (8)	49 (15)
Efficacy		
N	336	267
Mean (SD)	37.2 (13.7)	36.5 (14.3)
Median (IQR)	37.5 (33.3 - 50.0)	37.5 (25.0 - 50.0)
Unknown (%)	51 (13)	51 (16)
Speed of development		
N	296	0
Mean (SD)	24.0 (16.0)	N/A
Median (IQR)	25.0 (12.5 - 33.3)	N/A
Unknown (%)	91 (24)	N/A
Side effects		
N	353	277
Mean (SD)	21.0 (14.6)	19.4 (16.1)
Median (IQR)	16.7 (8.3 - 25.0)	16.7 (8.3 - 25.0)
Unknown (%)	34 (9)	41 (13)
Total score		
N	255	0
Mean (SD)	24.0 (9.3)	N/A
Median (IQR)	23.8 (18.0 - 28.9)	N/A
Unknown (%)	132 (34)	N/A
Total score*		
N	309	234
Mean (SD)	24.7 (9.5)	23.9 (10.3)
Median (IQR)	23.9 (18.9 - 30.0)	22.8 (17.2 - 29.2)
Unknown (%)	78 (20)	84 (26)

N = number N/A = not applicable at this timepoint; SD= Standard Deviation; IQR= Interquartile Range

*excluded question regarding speed of vaccine development

3c Vaccine related beliefs- Oxford Complacency and Confidence Scale- Children

	Patient-reported (N = 56)	Parent-reported (N = 58)
Importance		
N	53	56
Mean (SD)	16.8 (9.4)	16.3 (10.2)
Median (IQR)	15.0 (10.0 - 25.0)	15.0 (10.0 - 25.0)
Unknown (%)	3 (5)	2 (3)
Efficacy		
N	51	57
Mean (SD)	35.3 (14.4)	31.9 (12.5)
Median (IQR)	37.5 (25.0 - 50.0)	33.3 (25.0 - 41.7)
Unknown (%)	5 (9)	1 (2)
Speed of development		
N	43	47
Mean (SD)	26.2 (15.9)	31.0 (16.7)
Median (IQR)	25.0 (16.7 - 33.3)	33.3 (16.7 - 50.0)
Unknown (%)	13 (23)	11 (19)
Side effects		
N	50	56
Mean (SD)	20.9 (13.0)	20.8 (11.6)
Median (IQR)	16.7 (12.5 - 25.0)	16.7 (16.7 - 25.0)
Unknown (%)	6 (11)	2 (3)
Total score		
N	40	47
Mean (SD)	24.0 (8.0)	25.0 (8.7)
Median (IQR)	23.5 (18.2 - 29.2)	24.6 (20.8 - 28.9)
Unknown (%)	16 (29)	11 (19)
Total score*		
N	49	56
Mean (SD)	24.1 (8.2)	22.9 (8.6)
Median (IQR)	23.3 (18.9 - 27.8)	21.8 (16.9 - 26.8)
Unknown (%)	7 (12)	2 (3)

N = number N/A = not applicable at this timepoint; SD = Standard Deviation; IQR= Interquartile Range

*excluded question regarding speed of vaccine development

3d Grade and attribution of investigator-reported Serious Adverse Events

Serious adverse events (SAEs) recorded from medical record reviews were graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

	Adults n (%- 95% CI)		Children n (%- 95% CI)	
	Dose 1-2*	Dose 3**	Dose 1-2*	Dose 3**
Any SAE				
No	337 (88; 85-91)	295 (97; 95-99)	71 (70; 60-78)	51 (81; 69-90)
Yes	45 (12; 9-15)	8 (3; 1-5)	31 (30; 22-40)	12 (19; 10-31)
Number of SAE				
0	337 (88; 85-91)	295 (97; 95-99)	71 (70; 60-78)	51 (81; 69-90)
1	31 (8; 6-11)	7 (2; 1-5)	20 (20; 12-29)	10 (16; 8-27)
2	11 (3; 1-5)	1 (0; 0-2)	8 (8; 3-15)	2 (3; 0-11)
3	2 (1; 0-2)	0	2 (2; 0-7)	0
4+	1 (0; 0-1)	0	1 (1; 0-5)	0
Worst grade				
1	3 (1; 0-2)	0 (0; 0-1)	4 (4; 1-10)	6 (10; 4-20)
2	6 (2; 1-3)	0 (0; 0-1)	3 (3; 1-8)	4 (6; 2-15)
3	32 (8; 6-12)	8 (3; 1-5)	21 (21; 13-30)	2 (3; 0-11)
4	2 (1; 0-2)	0 (0; 0-1)	2 (2; 0-7)	0
5	2 (1; 0-2)	0	0	0
Attributable to vaccine				
Unlikely	41 (11; 8-14)	8 (3; 1-5)	17 (17; 10-25)	6 (10; 4-20)
Possible	4 (1; 0-3)	0 (0; 0-1)	14 (14; 8-22)	3 (5; 1-13)
Attributed	0	0	0	3 (5; 1-13)

Time period relates to *dose 1 until one month post-dose 2 and **dose 3 until one month after.

SAE = Serious Adverse Event; N = number; CI = confidence interval

3e Investigator-determined attribution of Serious Adverse Events

	Adults	Children
Definitely or very likely related		
Fever	0	2
Headache	0	1
Possibly related		
Fever	1	20
Mucositis	0	2
Rash	1	0
Upper respiratory symptoms	1	0
Pulmonary embolism	1*	0
Stroke	1*	0

* Same participant, who suffered pulmonary embolism 5 days post initial BNT162b2 vaccine then an ischemic stroke 7 days later, in the context of untreated malignancy and intercurrent pneumonia.

Note: One adult with comorbid ischaemic heart disease had a fatal myocardial infarction six weeks after the second BNT162b2 dose, outside the window for SAE reporting.

3f Category of Participant reported adverse events

Participant reported adverse events (AE) were recorded according to selected questions from PROCTCAE (Appendix 1c).

Dose	Adults		Children	
	n* / N	% (95% CI)	n / N	% (95% CI)
Local side effect (at injection site)				
Dose 1	240 / 369	65 (60-70)	46 / 54	85 (73-93)
2	245 / 365	67 (62-72)	19 / 28	68 (48-84)
3	196 / 286	69 (63- 74)	21 / 27	78 (58-91)
Systemic side effect				
Dose 1	178 / 353	50 (45-56)	26 / 50	52 (37-66)
2	217 / 351	62 (57-67)	16 / 27	59 (39-78)
3	159 / 273	58 (52-64)	14 / 26	54 (33-73)
Other side effect or adverse event				
Dose 1	108 / 371	29 (25-34)	18 / 54	33 (21-47)
2	117 / 366	32 (27-37)	8 / 28	29 (13-49)
3	102 / 288	35 (30-41)	10 / 26	38 (20-59)
Healthcare utilisation**				
Dose 1	29 / 315	9 (6-13)	13 / 53	25 (14-38)
2	35 / 347	10 (7-14)	2 / 26	8 (1- 25)
3	17 / 274	6 (4-10)	8 / 26	31 (14-52)
Delay or interruption to cancer treatment				
Dose 1	6 / 370	2 (1-3)	4 / 54	7 (2-18)
2	14 / 365	4 (2-6)	0 / 27	0 (0-13)
3	6 / 288	2 (1-4)	1 / 26	4 (0-20)

*n= number reporting an adverse effect; N=total number of respondents at timepoint; CI = Confidence Interval

**unscheduled visit to doctor or hospital

3g Specific Participant reported adverse events

	Dose	Adults		Children	
		n/N	% (95% CI)	n/N	% (95% CI)
Pain at injection site					
	Dose 1	224 / 371	60 (55- 65)	45 / 54	83 (71- 92)
	2	229 / 367	62 (57- 67)	17 / 28	61 (41- 78)
	3	180 / 288	62 (57- 68)	20 / 27	74 (54- 89)
Medication for side effects					
	Dose 1	105 / 371	28 (24- 33)	17 / 54	31 (20- 46)
	2	116 / 367	32 (27- 37)	8 / 28	29 (13- 49)
	3	100 / 288	35 (29- 41)	10 / 27	37 (19- 58)
Fatigue					
	Dose 1	75 / 371	20 (16- 25)	11 / 54	20 (11- 34)
	2	114 / 367	31 (26- 36)	12 / 28	43 (24- 63)
	3	83 / 288	29 (24- 34)	7 / 26	27 (12- 48)
Muscle pain					
	Dose 1	56 / 367	15 (12- 19)	9 / 53	17 (8- 30)
	2	87 / 363	24 (20- 29)	5 / 28	18 (6- 37)
	3	72 / 283	25 (20- 31)	4 / 26	15 (4- 35)
Headache					
	Dose 1	66 / 371	18 (14- 22)	9 / 54	17 (8- 29)
	2	80 / 367	22 (18- 26)	6 / 28	21 (8- 41)
	3	56 / 288	19 (15- 24)	4 / 26	15 (4- 35)
Redness or swelling at injection site					
	Dose 1	48 / 367	13 (10- 17)	9 / 54	17 (8- 20)
	2	63 / 363	17 (14- 22)	1 / 28	4 (0- 18)
	3	62 / 283	22 (17- 27)	3 / 27	11 (2- 29)

	Dose	Adults		Children	
		n/N	% (95% CI)	n/N	% (95% CI)
Shivering or shaking chills					
	Dose 1	44 / 362	12 (9- 16)	8 / 52	15 (7- 28)
	2	57 / 354	16 (12- 20)	7 / 27	26 (11- 46)
	3	53 / 277	19 (15- 24)	5 / 26	19 (7- 39)
Joint pain					
	Dose 1	40 / 371	11 (8- 14)	5 / 54	9 (3- 20)
	2	63 / 367	17 (13- 21)	1 / 28	4 (0- 18)
	3	62 / 288	22 (17- 27)	0 / 26	0 (0- 13)
Itch at injection site					
	Dose 1	44 / 371	12 (9- 16)	10 / 54	19 (9- 31)
	2	57 / 367	16 (12- 20)	4 / 28	14 (4- 33)
	3	47 / 288	16 (12- 21)	6 / 27	22 (9- 42)
Fever					
	Dose 1	27 / 351	8 (5- 11)	6 / 50	12 (5- 24)
	2	54 / 351	15 (12- 20)	3 / 25	12 (3- 31)
	3	56 / 277	20 (16- 25)	4 / 26	15 (4- 35)
Nausea					
	Dose 1	27 / 369	7 (5- 10)	4 / 54	7 (2- 18)
	2	39 / 367	11 (8- 14)	5 / 28	18 (6- 37)
	3	21 / 285	7 (5- 11)	4 / 26	15 (4- 35)
Diarrhoea					
	Dose 1	17 / 371	5 (3- 7)	5 / 54	9 (3- 20)
	2	26 / 367	7 (5- 10)	0 / 28	0 (0- 12)
	3	21 / 288	7 (5- 11)	2 / 26	8 (1- 25)

	Dose	Adults		Children	
		n/N	% (95% CI)	n/N	% (95% CI)
Hospital admission					
	Dose 1	20 / 339	6 (4- 9)	9 / 52	17 (8- 30)
	2	16 / 347	5 (3- 7)	2 / 26	8 (1- 25)
	3	8 / 273	3 (1- 6)	5 / 26	19 (7- 39)
Other systemic side effect					
	Dose 1	13 / 371	4 (2- 6)	13 / 371	4 (2- 6)
	2	19 / 367	5 (3- 8)	19 / 367	5 (3- 8)
	3	15 / 288	5 (3- 8)	15 / 288	5 (3- 8)
Emergency department attendance					
	Dose 1	10 / 330	3 (1- 6)	7 / 54	13 (5- 25)
	2	15 / 364	4 (2- 7)	1 / 27	4 (0- 19)
	3	3 / 286	1 (0- 3)	6 / 26	23 (9- 44)
Local doctor visit					
	Dose 1	10 / 365	3 (1- 5)	2 / 53	4 (0- 13)
	2	15 / 363	4 (2- 7)	1 / 27	4 (0- 19)
	3	7 / 285	2 (1- 5)	0 / 26	0 (0- 13)
Delays or interruption to anticancer treatment					
	Dose 1	6 / 370	2 (1- 3)	4 / 54	7 (2- 18)
	2	14 / 365	4 (2- 6)	0 / 27	0 (0- 13)
	3	6 / 288	2 (1- 4)	1 / 26	4 (0- 20)
Vomiting					
	Dose 1	3 / 369	1 (0- 2)	3 / 54	6 (1- 15)
	2	11 / 366	3 (2- 5)	2 / 28	7 (1- 24)
	3	5 / 286	2 (1- 4)	2 / 26	8 (1- 25)

	Dose	Adults		Children	
		n/N	% (95% CI)	n/N	% (95% CI)
Other local side effect					
	Dose 1	1 / 371	0 (0- 1)	1 / 54	2 (0- 10)
	2	3 / 367	1 (0- 2)	0 / 28	0 (0- 12)
	3	2 / 288	1 (0- 2)	1 / 27	4 (0- 19)
Treatment for blood clot					
	Dose 1	3 / 371	1 (0- 2)	1 / 54	2 (0- 10)
	2	1 / 366	0 (0- 2)	0 / 27	0 (0- 13)
	3	2 / 288	1 (0- 2)	0 / 26	0 (0- 13)
Other side effect					
	Dose 1	0 / 371	0 (0- 1)	0 / 54	0 (0- 7)
	2	0 / 367	0 (0- 1)	0 / 28	0 (0- 12)
	3	0 / 288	0 (0- 1)	0 / 27	0 (0- 13)

*n = number reporting an adverse effect; N = total number of respondents at timepoint; CI = Confidence Interval ED = Emergency Department

**unscheduled visit to doctor or hospital

3h Association of worst patient reported adverse event with receipt of 3rd vaccine dose

Worst side effect*	Received 3 rd dose n / N (%)	OR (95% CI)
None	37 / 48 (77)	—
Mild	124 / 148 (84)	1.54 (0.7- 3.4)
Moderate	98 / 108 (91)	2.91 (1.1- 7.6)
Severe	48 / 58 (83)	1.43 (0.6- 3.8)
Serious	11 / 18 (61)	0.47 (0.2- 1.5)

Multiple imputation was conducted to account for missing data.

The severity of participant-reported AE after the first two vaccinations was not significantly associated with receipt of a third dose [p=0.48]

*Severity self-reported by 5-point Likert scale (Appendix 1b).

n = number reporting an adverse effect; N = total number of respondents at timepoint; OR = Odds Ratio; CI = Confidence Interval

3i Investigator- reported adverse events by vaccine type

Incidence of investigator-reported adverse events observed between dose 1 and one month post-dose 2; and between dose 3 and 1 month post dose 3, for patients over 60 years, comparing those who received an mRNA vaccine (BNT162b2 or mRNA-1273) and those who received the viral vector (ChadOx1-S) vaccine. 1 patient received a different vaccine for dose 1 and 2 and was excluded.

Dose	Events / Patients n* / N (%)		OR ⁺ (95% CI)	p-value	RR ⁺⁺ (95% CI)	p-value
	mRNA	Viral vector				
Thrombotic event						
Dose 1 - 2*	2 / 134 (1)	0 / 37 (0)	NR	0.32	NR	0.22
3**	0 / 141 (0)	0 / 2 (0)	NR	—	NR	—
Allergic reaction						
Dose 1 - 2	0 / 134 (0)	0 / 37 (0)	NR	—	NR	—
3	0 / 141 (0)	0 / 2 (0)	NR	—	NR	—
Decline in performance status***						
Dose 1 - 2	7 / 132 (5)	4 / 37 (11)	2.16 (0.5 - 7.6)	0.26	1.21 (0.3 - 4.0)	0.76
3	6 / 134 (4)	0 / 2 (0)	NR	0.67	NR	0.67
Lymphadenopathy						
Dose 1 - 2	8 / 134 (6)	5 / 37 (14)	2.46 (0.7 - 7.9)	0.15	1.35 (0.4 - 4.0)	0.60
3	3 / 141 (2)	0 / 2 (0)	NR	0.77	NR	0.77
Treatment delay						
Dose 1 - 2	8 / 134 (6)	4 / 37 (11)	1.91 (0.5 - 6.5)	0.33	1.08 (0.3 - 3.4)	0.90
3	7 / 141 (5)	0 / 2 (0)	NR	0.65	NR	0.66
Treatment modification						
Dose 1 - 2	21 / 134 (16)	5 / 37 (14)	0.84 (0.3 - 2.3)	0.74	0.51 (0.2 - 1.3)	0.15
3	15 / 141 (11)	0 / 2 (0)	NR	0.50	NR	0.52
Treatment delay and/or modification						
Dose 1 - 2	23 / 134 (17)	7 / 37 (19)	1.13 (0.4 - 2.8)	0.81	0.66 (0.3 - 1.5)	0.31
3	20 / 141 (14)	0 / 2 (0)	NR	0.44	NR	0.45

* between dose 1 and one month post-dose 2; ** between dose 3 and one month afterwards; *** Eastern Cooperative Group performance status

+ OR=odds ratio; estimated from a logistic regression model for each adverse event at each time point; ++ RR = relative rate: as the period between doses 1 and 2 differed by vaccine type, a log-link Poisson GLM including the log of the actual time period as an offset was fitted to estimate the relative rate.

NR = not recordable as no events observed in one or both vaccine groups.

Allergic reactions were recorded separately for each dose; we have combined doses 1 & 2 here for consistency

*n = number reporting an adverse effect; N = total number of respondents at timepoint CI = Confidence Interval

3j Serious Adverse Events by vaccine type

The number of SAEs at during each reporting period were compared between vaccine types, relative rate was adjusted according to exposure time.

Dose	SAEs / Patients ((SAE rate per 30 person days)#)		Unadjusted		Adjusted*	
	mRNA (BNT162b2)	Viral vector (ChAdOx1-S)	RR (95% CI)	p-value	RR (95% CI)	p-value
1 and 2	12 / 135 (0.09)	10 / 37 (0.27)	3.04 (1.28, 7.05)	0.013	1.81 (0.76, 4.20)	0.17
3	4 / 140 (0.03)	0 / 2 (0.00)	—	0.74	—	0.74

#Fitted rate of SAEs per 30 person-days under unadjusted log-link Poisson generalised linear model (GLM),

*exposure time was adjusted for by adjusted log-link Poisson GLM, to account for differences in dosing schedule and subsequent time at risk during each reporting period. Median exposure time from dose 1 to 1 month post dose 2 was 51 days for mRNA recipients and 80 days for viral vector recipients.

Adj. Adjusted (but I think just simplify the table heading to adjusted)

Exp. Exp. exposure (but as above, covered in the footer)

CI Confidence Interval

RR Relative Rate

3k Participant-reported adverse effects by vaccine type

Participant-reported side effects were measured by selected PROCTCAE items (Appendix 1c) in patients over 60 years to compare mRNA and viral vector vaccine types.

Events / Respondents (%) by vaccine type		
	mRNA	Viral vector
Pain at injection site		
Dose 1	74 / 135 (55)	15 / 39 (38)
2	71 / 134 (53)	8 / 35 (23)
3	71 / 133 (53)	1 / 2 (50)
Redness or swelling at injection site		
Dose 1	14 / 132 (11)	5 / 39 (13)
2	16 / 133 (12)	3 / 34 (9)
3	25 / 130 (19)	2 / 2 (100)
Itch at injection site		
Dose 1	17 / 135 (13)	5 / 39 (13)
2	16 / 134 (12)	3 / 35 (9)
3	22 / 133 (17)	0 / 2 (0)
Medication for side effects		
Dose 1	31 / 135 (23)	8 / 39 (21)
2	32 / 134 (24)	4 / 35 (11)
3	36 / 133 (27)	1 / 2 (50)
Fatigue		
Dose 1	24 / 135 (18)	4 / 39 (10)
2	33 / 134 (25)	5 / 35 (14)
3	35 / 133 (26)	0 / 2 (0)
Muscle pain		
Dose 1	21 / 134 (16)	5 / 39 (13)
2	24 / 133 (18)	6 / 33 (18)
3	28 / 129 (22)	0 / 2 (0)
Joint pain		
Dose 1	14 / 135 (10)	6 / 39 (15)
2	20 / 134 (15)	6 / 35 (17)
3	30 / 133 (23)	2 / 2 (100)

Events / Respondents (%) by vaccine type		
	mRNA	Viral vector
Shivering or shaking chills		
Dose 1	14 / 131 (11)	7 / 38 (18)
2	15 / 130 (12)	6 / 33 (18)
3	24 / 125 (19)	1 / 2 (50)
Headache		
Dose 1	20 / 135 (15)	5 / 39 (13)
2	22 / 134 (16)	3 / 35 (9)
3	17 / 133 (13)	2 / 2 (100)
Fever		
Dose 1	10 / 126 (8)	1 / 38 (3)
2	12 / 126 (10)	1 / 32 (3)
3	20 / 127 (16)	0 / 2 (0)
Nausea		
Dose 1	11 / 134 (8)	3 / 39 (8)
2	11 / 134 (8)	3 / 35 (9)
3	11 / 132 (8)	0 / 2 (0)
Diarrhoea		
Dose 1	9 / 135 (7)	1 / 39 (3)
2	9 / 134 (7)	2 / 35 (6)
3	8 / 133 (6)	0 / 2 (0)
Hospital admission		
Dose 1	7 / 125 (6)	0 / 33 (0)
2	4 / 125 (3)	2 / 31 (6)
3	4 / 123 (3)	0 / 2 (0)
Local doctor visit		
Dose 1	6 / 132 (5)	0 / 39 (0)
2	6 / 132 (5)	2 / 34 (6)
3	4 / 131 (3)	0 / 2 (0)
Other systemic side effect		
Dose 1	5 / 135 (4)	1 / 39 (3)
2	4 / 134 (3)	1 / 35 (3)
3	2 / 133 (2)	1 / 2 (50)
Delays in interruption to anticancer treatment		
Dose 1	2 / 134 (1)	0 / 39 (0)
2	5 / 133 (4)	2 / 35 (6)
3	4 / 133 (3)	0 / 2 (0)

Events / Respondents (%) by vaccine type		
	mRNA	Viral vector
Vomiting		
Dose 1	1 / 135 (1)	0 / 37 (0)
2	5 / 134 (4)	2 / 35 (6)
3	3 / 133 (2)	0 / 2 (0)
Emergency department attendance		
Dose 1	2 / 127 (2)	0 / 29 (0)
2	5 / 132 (4)	1 / 34 (3)
3	1 / 132 (1)	0 / 2 (0)
Treatment for blood clot		
Dose 1	0 / 135 (0)	2 / 39 (5)
2	0 / 133 (0)	1 / 35 (3)
3	2 / 133 (2)	0 / 2 (0)
Other local side effect		
Dose 1	0 / 135 (0)	0 / 39 (0)
2	0 / 134 (0)	2 / 35 (6)
3	0 / 133 (0)	0 / 2 (0)

3I Impact of sequential vaccine doses on health-related quality of life in adults

Quality of life measured using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 item instrument (EORTC QLQC-30). Multiple imputations were completed to account for missing data.

	Dose	Observed				Imputed				Difference	
		N	Pre Mean (SD)	N	Post Mean (SD)	N	Pre Mean (SD)	N	Post Mean (SD)	Est (95% CI)	p-value
Primary outcomes											
Global health status / QoL	1	377	68.8 (20.5)	366	67.3 (22.2)	386	68.8 (20.6)	386	67.4 (22.1)	-1.4 (-3.4 - 0.6)	0.16
	2	368	65.9 (22.6)	361	66.9 (21.5)	378	66.2 (22.6)	378	66.9 (21.6)	0.7 (-1.2 - 2.6)	0.48
Summary score	1	369	82.4 (14.3)	360	83.0 (14.5)	384	82.4 (14.4)	384	82.9 (14.7)	0.5 (-0.5 - 1.6)	0.30
	2	362	82.2 (15.4)	359	81.8 (16.7)	377	82.6 (15.3)	377	81.8 (16.6)	-0.8 (-1.9 - 0.3)	0.17
Functional scales											
Physical functioning	1	379	81.7 (19.7)	368	82.2 (18.9)	387	81.6 (19.8)	387	82.2 (18.9)	0.7 (-0.7 - 2.1)	0.35
	2	369	81.1 (20.9)	362	81.9 (21.0)	378	81.3 (20.8)	378	82.0 (21.0)	0.7 (-0.9 - 2.2)	0.40
Role functioning	1	379	76.5 (27.3)	367	77.8 (26.7)	387	76.4 (27.3)	387	77.7 (26.8)	1.3 (-1.2 - 3.8)	0.29
	2	369	77.7 (27.2)	362	76.6 (29.1)	378	78.0 (27.1)	378	76.7 (28.9)	-1.3 (-3.7 - 1.1)	0.28
Emotional functioning	1	377	80.4 (19.4)	367	81.2 (20.2)	386	80.2 (19.6)	386	81.3 (20.2)	1.1 (-0.5 - 2.8)	0.19
	2	368	80.2 (20.1)	361	79.8 (22.8)	378	80.4 (20.1)	378	79.9 (22.7)	-0.5 (-2.1 - 1.1)	0.56
Cognitive functioning	1	377	85.0 (19.6)	367	84.8 (20.4)	386	84.8 (19.8)	386	84.9 (20.2)	0.0 (-1.8 - 1.8)	0.97
	2	369	83.5 (20.7)	361	82.8 (22.1)	378	83.7 (20.6)	378	82.8 (22.1)	-0.9 (-2.8 - 1.0)	0.34
Social functioning	1	376	80.0 (26.0)	367	81.4 (26.5)	386	79.9 (26.0)	386	81.4 (26.5)	1.5 (-1.1 - 4.0)	0.25
	2	368	80.6 (27.4)	361	79.6 (28.7)	378	80.9 (27.2)	378	79.6 (28.6)	-1.3 (-3.7 - 1.0)	0.26

Symptom scales /items											
Fatigue	1	377	32.2 (24.5)	367	31.4 (24.7)	386	32.4 (24.5)	386	31.4 (24.6)	-1.0 (-3.1 - 1.2)	0.39
	2	369	33.3 (24.5)	361	33.7 (26.7)	378	33.0 (24.4)	378	33.7 (26.7)	0.6 (-1.4 - 2.7)	0.54
Nausea & vomiting	1	377	6.1 (12.9)	366	5.9 (12.7)	386	6.3 (13.3)	386	6.0 (12.8)	-0.4 (-1.7 - 1.0)	0.58
	2	369	6.5 (13.7)	361	6.7 (13.2)	378	6.5 (13.7)	378	6.8 (13.2)	0.3 (-1.0 - 1.5)	0.66
Pain	1	379	20.2 (23.5)	367	22.8 (25.6)	387	20.2 (23.6)	387	22.8 (25.5)	2.6 (0.4 - 4.7)	0.020
	2	369	21.7 (26.8)	362	24.2 (27.5)	378	21.5 (26.7)	378	24.2 (27.5)	2.7 (0.4 - 5.0)	0.021
Dyspnoea	1	378	13.9 (21.3)	366	12.4 (20.2)	387	13.9 (21.2)	387	12.3 (20.2)	-1.6 (-3.6 - 0.4)	0.11
	2	369	15.3 (22.6)	362	15.1 (22.3)	378	15.0 (22.5)	378	15.2 (22.3)	0.1 (-1.8 - 2.1)	0.89
Insomnia	1	376	25.0 (27.0)	366	23.6 (28.1)	386	25.3 (27.3)	386	23.3 (27.9)	-2.0 (-4.4 - 0.4)	0.096
	2	369	23.6 (26.4)	360	23.8 (27.5)	378	23.4 (26.3)	378	23.7 (27.6)	0.3 (-2.2 - 2.8)	0.80
Appetite loss	1	375	13.5 (25.1)	364	13.1 (22.5)	385	13.4 (25.0)	385	13.1 (22.4)	-0.4 (-2.6 - 1.9)	0.75
	2	367	13.2 (23.6)	360	14.2 (24.2)	378	12.9 (23.4)	378	14.1 (24.1)	1.2 (-0.8 - 3.2)	0.25
Constipation	1	375	12.1 (23.0)	365	13.4 (23.8)	386	12.2 (23.2)	386	13.1 (23.6)	1.0 (-1.3 - 3.2)	0.39
	2	366	11.2 (21.2)	361	12.0 (22.0)	378	11.1 (21.1)	378	12.0 (22.1)	0.9 (-1.2 - 3.1)	0.40
Diarrhoea	1	377	8.1 (18.2)	366	7.1 (17.6)	386	8.2 (18.1)	386	7.0 (17.5)	-1.1 (-3.0 - 0.7)	0.23
	2	366	9.4 (20.2)	361	7.9 (18.9)	378	9.2 (20.0)	378	8.3 (19.6)	-0.9 (-2.9 - 1.0)	0.35
Financial difficulties	1	375	14.2 (26.1)	367	13.4 (26.3)	386	14.4 (26.3)	386	13.5 (26.6)	-0.8 (-2.9 - 1.2)	0.41
	2	368	13.5 (25.8)	361	12.7 (25.8)	378	13.3 (25.6)	378	12.8 (25.9)	-0.5 (-2.3 - 1.4)	0.61

N = number; SD = Standard Deviation; QoL = Quality of Life; Est = Estimated; CI= Confidence Interval

3m Impact of sequential doses on health-related quality of life in children

i. Child reported questionnaires

	Dose	Observed				Imputed				Difference	
		N	Pre Mean (SD)	N	Post Mean (SD)	N	Pre Mean (SD)	N	Post Mean (SD)	Est (95% CI)	p-value
Primary outcomes											
Total score	1	45	70.1 (19.1)	39	71.2 (17.5)	53	67.6 (19.7)	53	71.8 (17.2)	4.3 (0.9- 7.7)	0.015
	2	45	72.8 (17.1)	32	74.5 (15.7)	48	72.0 (17.1)	48	75.7 (15.5)	3.7 (0.7- 6.8)	0.017
Dimensions											
Pain and hurt	1	45	68.1 (27.1)	39	73.4 (23.5)	53	66.7 (27.0)	53	73.8 (23.3)	7.2 (-0.3- 14.7)	0.060
	2	45	72.8 (26.0)	32	75.4 (22.8)	48	72.3 (26.2)	48	74.7 (22.8)	2.4 (-5.1- 10.0)	0.51
Nausea	1	45	68.9 (27.4)	39	74.5 (22.0)	53	65.4 (28.7)	53	73.9 (21.7)	8.5 (3.5- 13.6)	0.002
	2	45	73.4 (24.2)	32	74.2 (23.7)	48	71.6 (25.0)	48	74.5 (23.9)	2.9 (-1.4- 7.2)	0.18
Procedural anxiety	1	45	68.3 (30.1)	39	69.0 (29.4)	53	68.7 (29.6)	53	70.9 (28.2)	2.1 (-6.1- 10.4)	0.60
	2	45	73.5 (27.4)	32	77.9 (27.2)	48	74.8 (27.1)	48	79.8 (25.9)	5.0 (-1.0- 11.0)	0.099
Treatment anxiety	1	45	81.9 (22.1)	39	77.4 (26.1)	53	79.6 (23.2)	53	79.9 (24.5)	0.3 (-5.5- 6.1)	0.92
	2	45	82.6 (23.0)	32	86.2 (24.1)	48	83.0 (22.5)	48	88.1 (22.2)	5.1 (0.5- 9.8)	0.031
Worry	1	45	70.9 (25.3)	39	67.5 (25.5)	53	67.6 (26.6)	53	68.1 (24.9)	0.5 (-5.5- 6.5)	0.86
	2	45	72.4 (23.8)	32	74.7 (21.8)	48	71.5 (23.9)	48	76.1 (21.7)	4.6 (-0.6- 9.8)	0.083
Cognitive problems	1	45	60.9 (25.2)	39	62.7 (24.1)	53	58.8 (24.9)	53	61.8 (23.5)	3.0 (-1.6- 7.6)	0.20
	2	45	63.4 (20.9)	32	61.1 (19.7)	48	62.4 (21.6)	48	63.5 (19.3)	1.1 (-3.9- 6.0)	0.66
Perceived physical appearance	1	45	69.8 (27.1)	39	72.6 (26.5)	53	68.1 (27.3)	53	73.3 (26.0)	5.2 (-1.9- 12.2)	0.15
	2	45	73.9 (27.9)	32	76.0 (30.6)	48	72.3 (28.4)	48	77.5 (30.0)	5.2 (-2.0- 12.4)	0.15
Communication	1	45	78.3 (20.8)	39	76.5 (19.8)	53	76.4 (21.6)	53	76.8 (19.2)	0.4 (-6.0- 6.7)	0.91
	2	45	76.3 (19.5)	32	79.4 (17.5)	48	76.2 (19.7)	48	78.9 (16.8)	2.6 (-2.6- 7.9)	0.32

N = Number; SD = Standard Deviation; Est = Estimated; CI = Confidence Interval

ii. Parent reported questionnaires

Parent-reported Quality of Life (QoL) was collected using Pediatric Quality of Life Inventory™ (PedsQL) for children aged 5-19 years. Higher scores indicate better health related QoL.

	Dose	Observed				Imputed				Difference	
		N	Pre Mean (SD)	N	Post Mean (SD)	N	Pre Mean (SD)	N	Post Mean (SD)	Est (95% CI)	p-value
Primary outcomes											
Total score	1	54	72.1 (15.7)	55	74.2 (16.7)	70	71.5 (16.3)	70	72.4 (16.8)	0.9 (-2.0 - 3.7)	0.55
	2	49	70.9 (17.8)	45	73.1 (17.5)	56	70.4 (17.4)	56	73.5 (17.1)	3.1 (0.1 - 6.1)	0.046
Dimensions											
Pain and hurt	1	54	68.1 (25.4)	55	75.9 (22.0)	70	66.4 (26.1)	70	73.9 (21.5)	7.5 (1.8 - 13.1)	0.011
	2	50	71.5 (24.7)	46	72.6 (27.3)	58	72.1 (24.7)	58	72.5 (27.0)	0.3 (-4.5 - 5.2)	0.88
Nausea	1	54	73.1 (23.9)	55	75.4 (24.3)	70	72.5 (24.2)	70	72.1 (25.0)	-0.4 (-5.4 - 4.7)	0.88
	2	49	71.3 (25.1)	46	74.2 (25.5)	57	70.5 (24.8)	57	74.0 (24.9)	3.5 (-0.7 - 7.7)	0.10
Procedural anxiety	1	54	71.1 (28.5)	55	72.4 (28.1)	70	72.6 (27.2)	70	72.1 (27.9)	-0.5 (-6.1 - 5.1)	0.86
	2	49	72.2 (29.5)	45	74.4 (25.6)	56	73.1 (28.3)	56	75.0 (25.7)	1.9 (-3.6 - 7.5)	0.48
Treatment anxiety	1	54	81.2 (22.7)	55	80.6 (26.5)	70	79.5 (24.1)	70	80.8 (25.9)	1.3 (-4.3 - 6.8)	0.65
	2	49	77.2 (27.6)	45	80.9 (26.3)	56	77.5 (26.7)	56	82.0 (25.2)	4.5 (-0.4 - 9.5)	0.073
Worry	1	54	74.1 (21.6)	55	75.0 (21.8)	70	73.8 (21.5)	70	74.1 (21.7)	0.3 (-3.9 - 4.5)	0.90
	2	49	71.3 (24.4)	45	71.3 (23.6)	56	69.5 (24.1)	56	72.6 (23.7)	3.1 (-1.5 - 7.7)	0.18
Cognitive problems	1	53	60.9 (22.3)	54	64.9 (21.4)	70	60.3 (22.3)	70	63.1 (21.5)	2.8 (-1.7 - 7.4)	0.22
	2	49	62.1 (21.0)	45	63.3 (20.6)	56	61.4 (21.2)	56	63.9 (20.0)	2.5 (-2.2 - 7.1)	0.29
Perceived physical appearance	1	53	76.7 (24.4)	54	75.8 (22.1)	70	75.0 (24.5)	70	74.7 (22.3)	-0.3 (-4.6 - 4.0)	0.88
	2	49	70.9 (27.8)	44	76.3 (26.4)	56	70.5 (27.5)	56	76.0 (25.9)	5.4 (-2.0 - 12.8)	0.15

	Dose	Observed				Imputed				Difference Est (95% CI)	p-value
		N	Pre Mean (SD)	N	Post Mean (SD)	N	Pre Mean (SD)	N	Post Mean (SD)		
Communication	1	52	75.7 (19.9)	54	78.2 (20.8)	70	76.1 (20.2)	70	77.5 (20.8)	1.4 (-3.1 - 6.0)	0.52
	2	49	75.9 (20.7)	44	78.0 (20.8)	56	75.7 (20.8)	56	77.7 (21.5)	2.0 (-3.1 - 7.0)	0.43

N = Number; SD = Standard Deviation; Est = Estimated; CI = Confidence Interval

3n Baseline health-related quality of life and vaccine related beliefs

Scores from the baseline Oxford vaccine Confidence and Complacency Scale were correlated with domains in the baseline quality of life questionnaires.

QoL scale	N	Correlation (95% CI)*
Adults (QLQ-C30)		
Emotional functioning	246	-0.18 (-0.31 - 0.04)
Global health status	246	-0.17 (-0.29 - 0.03)
Summary score	241	-0.17 (-0.30 - 0.04)
Children** (PedsQL)		
Worry	35	-0.02 (-0.35 - 0.32)
Procedural anxiety	35	-0.13 (-0.44 - 0.21)
Treatment anxiety	35	-0.19 (-0.52 - 0.15)
Communication	35	-0.36 (-0.63 - 0.02)
Total score	35	-0.39 (-0.68 - 0.08)

N = Number of responses; CI = Confidence Interval;

* using an estimated Spearman correlation coefficient r

** if child's response was unavailable, parent response was used